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227* CT scores correlate with survival in cystic ﬁbrosis patients
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Rationale: Waiting list mortality for patients awaiting lung transplantation (LTX)
ranges from 15−40%. Inclusion of CT related parameters may improve currently
used prediction models for survival.
Objectives: To investigate the relation between CT scores and waiting list mortality
in a large cohort of CF patients screened for LTX.
Methods: Clinical data and chest CT scans of 411 CF patients between 1990
and 2005 were collected from 17 centers worldwide. CTs were scored with the
Severe Advanced Lung Disease (SALD) 4 category scoring system, including
the components ‘infection/inﬂammation’ (INFL), air trappinghypoperfusion (AT),
normal/hyperperfusion (NL) and bulla/cysts (BUL). The volume for each compo-
nent was estimated on a 0–100% scale using semi-automated software. Survival
analysis included Kaplan–Meier curves and the log rank test. LTX was considered
a censoring event.
Results: Of 411 patients, 366 (186 males) entered the waiting list (mean age 24,
range 5−58 years). Of these patients, 67 had died on the waiting list, 263 underwent
LTX after a mean waiting period of 10 months and 36 were still awaiting LTX
after a mean waiting period of 20 months. Univariate analysis showed a decreased
survival with higher INFL scores (2-years survival lowest tertile 78%, decreasing
to 61% for highest tertile; ptrend < 0.001). Survival improved with higher NL scores
(ptrend = 0.004). No signiﬁcant relations were found for AT and BUL.
Conclusions: The volume of infection/inﬂammation as estimated by the SALD
scoring system correlates signiﬁcantly with survival. Statistical analysis to investi-
gate whether CT scores can improve survival prediction models is ongoing.
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Introduction: Cepacia syndrome (cep sy) is the most unfavourable clinical condi-
tion caused by B. cepacia complex (BCC) colonization in CF patients. Due to the
past BCC outbreak ~40% of the Czech adult CF population harbor BCC epidemic
strain ST-32.
Methods: All hospital records from adult CF patients during 2001–2010 were
evaluated for presence of cep sy. Cep sy was diagnosed if following criteria were
met: (i) WBC >25,000/ml and/or CRP >100mg/l), (ii) new multifocal inﬁltrates on
CXR, (iii) positive blood culture for BCC. Clinical characteristics of patients with
cep sy were compared to those with ST-32 who never developed cep sy.
Results: 13 episodes of cep sy were recorded in 12 patients (6M and 6 F; two
episodes occured in one patient). They were matched with 24 (12M and 12 F)
patients of similar age and length of ST-32 colonization (median 11.6 years). Both
groups did not differ signiﬁcantly in median (range) age: 25.6 (19.3–38.3) vs.
25.2 (18.0–31.6) years, presence of chronic P. aeruginosa infection: 2/12 vs. 3/24,
insulinotherapy (for IGT/DM): 5/12 vs. 10/24 and liver diasease: 3/12 vs. 4/24. The
group with cep sy had worse FEV1: 40 (24−65) vs. 61 (20–113) %pred. (p = 0.022)
and tended to have worse BMI: 19.8 (18.4–23.2) vs. 21.9 (14.0–31.2) kg/m2
(p = 0.18), higher serum IgG concentration: 19.3 (12.7–34.9) vs. 17.5 (8.5–32.2) g/l
(p = 0.22) and higher frequency of pancreatic insufﬁciency: 12/12 vs. 19/24
(p = 0.15).
Conclusions: Patients who developed cepacia syndrome had signiﬁcantly worse
pulmonary function and tended to have worse nutritional status, higher serum IgG
concentration and more frequent pancreatic insufﬁciency.
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Background: The pathogenic mechanisms of sensitization to Aspergillus are
unclear. Some authors propose speciﬁc Aspergillus IgE as an innocent bystander,
whereas others describe it as the major cause of TH2 driven asthma like disease.
Hypothesis: Lung function parameters in mild CF patients may be different in
patients without and with Aspergillus sensitization.
Methods: In our study, 35 CF patients (4−41 years) and 16 healthy controls were
investigated. Patients were assigned to two groups: Group 1 (n = 18) RAST negative;
group 2 (n = 17) RAST Aspergillus positive 2. Lung function parameters and
eNO were analyzed. All sensitized patients with a FEV1 >75% (n = 13) underwent
bronchial allergen challenge with Aspergillus.
Results: Lung function parameters (VC, FEV1, FEV1%VCmax) were signiﬁcantly
different compared to controls, but not within our two CF groups. After aller-
gen challenge, 9 of 13 patients responded with a signiﬁcant decrease of FEV1
(4 early-, 5 late-phase allergic reactions). 24 hours later, eNO signiﬁcantly increased
(10.6 ppb to 16.2 ppb; p< 0.05) and FEV1 decreased by 4.2% as an allergen-induced
TH2 shift.
Conclusion: Our study demonstrated the clinical relevance of Aspergillus for the
majority of sensitized CF patients. Current deﬁnition of allergic bronchial pul-
monary aspergillosis (ABPA) does not include the clinical relevance of Aspergillus-
induced asthma like disease in CF.
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Respiratory muscle function in patients with cystic ﬁbrosis (CF) can be assessed
by measurement of maximal inspiratory pressure (Pimax), maximal expiratory
pressure (Pemax), pressure time index of the respiratory muscles (PTImus), muscle
relaxation rate (MRR) and maximum rate of pressure development (MRPD).
Aims: To study respiratory muscle function indices in CF and to examine the possi-
ble effect of pulmonary function abnormalities to respiratory muscle performance,
in children and young adults with CF.
Material and Methods: One hundred forty-ﬁve patients and a control group
of 145 healthy subjects matched for age and gender were recruited. Respiratory
muscle function was assessed by measurement of PTImus, Pimax, Pemax, MRR
and MRPD. Pulmonary function evaluation consisted of forced expiratory volume
in 1 s (FEV1), forced vital capacity (FVC) and maximal expiratory ﬂow between
25% and 75% of VC (MEF25−75).
Results: Pimax and Pemax were signiﬁcantly lower in CF patients compared to the
control group (p< 0.05 and p< 0.01, respectively). PTImus values in CF patients
compared to healthy controls did not exhibit signiﬁcant differences. PTImus was
signiﬁcantly higher in CF patients with impaired pulmonary function. MRR during
Pemax (p< 0.05) and MRPD during Pemax (p< 0.001) were signiﬁcantly altered in
CF compared to the control group.
Conclusions: This study demonstrated that CF patients do not overall exhibit higher
PTImus values compared to the healthy population. Patients with affected standard
pulmonary function parameters, such as FEV1, FVC and MEF25−75, exhibit higher
PTImus values compared to CF patients with normal or less affected pulmonary
function indices.
